NOTE 7 – INTANGIBLE ASSETS, NET (Tables)

6 Months Ended

Jun. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of June 30, 2020 and December 31, 2019:

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of June 30, 2020 and December 31, 2019:

	June 30, 2020
	Gross Carrying Amount		Accumulated Amortization			Net  Amount		Weighted- Average  Remaining Amortization Period (yrs.)
Amortizable intangible assets:
Approved hormone therapy drug candidate patents	$	3,997,263	$	(609,982	)	$	3,387,281		12.5
Hormone therapy drug candidate patents (pending)		2,216,911		—			2,216,911		n/a
Non-amortizable intangible assets:
Multiple trademarks		338,681		—			338,681		indefinite
TOTAL	$	6,552,855	$	(609,982	)	$	5,942,873

	December 31, 2019
	Gross Carrying Amount		Accumulated Amortization			Net   Amount		Weighted- Average   Remaining Amortization Period (yrs.)
Amortizable intangible assets:
Approved hormone therapy drug candidate patents	$	3,463,082	$	(478,983	)	$	2,984,099		13
Hormone therapy drug candidate patents (pending)		1,979,299		—			1,979,299		n/a
Non-amortizable intangible assets:
Multiple trademarks		294,813		—			294,813		indefinite
TOTAL	$	5,737,194	$	(478,983	)	$	5,258,211

Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows

Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:

Year Ending  December 31,	Estimated Amortization
2020 (6 months)	$	135,495
2021	$	270,990
2022	$	270,990
2023	$	270,990
2024	$	270,990